Visiongain has published a new report entitled Cell & Gene Therapy Cold Chain Logistics Market Report 2025-2035 (Including Impact of U.S. Trade Tariffs): Forecasts by Component (Cryogenic Shippers, Cryogenic Storage Freezers, Ultra-Low Freezers, Cold Chain Management Systems, Shipment and Storage Medium, Cryogenic Packout Kits, Others), by Services (Transportation, Storage, Packaging), by Mode of Transport (Air Transport, Ground Transport, Water Transport), by Holding Temperature Range (Cryogenic, Refrigerated, Ambient, Others), by End-users (Biopharmaceutical and Biotechnology Companies, Academic & Research Institutes, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies.

The global cell and gene therapy cold chain logistics market is estimated at US$9,975.2 million in 2025 and is projected to grow at a CAGR of 16.5% during the forecast period 2025-2035.

Impact of the U.S. Trade Tariffs on the Global Cell and Gene Therapy Cold Chain Logistics Market 

The implementation of the U.S. trade tariffs on pharmaceutical imports, particularly targeting Chinese APIs and medical components, has introduced significant challenges for the global cell and gene therapy (CGT) cold chain logistics market. These tariffs have disrupted long-established supply chains, leading many biopharma companies to reconsider their sourcing strategies in order to mitigate geopolitical risks. As a result, firms are increasingly looking toward reshoring production or diversifying their supplier base to other regions. This shift places additional pressure on logistics providers, who must adapt their networks and capabilities to meet changing demand patterns while maintaining strict temperature and regulatory compliance standards required for CGT products.

In response to these tariffs, logistics providers are also experiencing increased demand for bonded warehouses, as importers seek to delay tariff payments and manage rising costs. This has led to a surge in infrastructure investment and operational expenses, particularly in cold storage. Additionally, to offset growing transportation costs, some companies are shifting to slower and less expensive shipping methods, which can pose risks to the stability and integrity of temperature-sensitive therapies. The cumulative effect of these trade policies underscores the need for more resilient, adaptive, and technology-enabled cold chain systems to safeguard the global distribution of cell and gene therapies amid evolving regulatory and economic landscapes.

Strong Clinical Pipeline and Increasing Approvals for Cell and Gene Therapy Products Driving the Demand for Cold Chain Logistics 

The cell and gene therapy sector is witnessing a rapid growth, driven by technological advancements and substantial investments in research and development. A growing number of clinical trials are being launched as major biopharmaceutical companies explore these therapies for a wide range of conditions beyond traditional genetic disorders. Recent studies have highlighted the therapeutic potential of cell-based treatments like regulatory T cells and mesenchymal stem cells in addressing autoimmune diseases, paving the way for broader clinical applications. 

Currently, there are approximately 1,000 cell and gene therapy candidates in the global development pipeline, reflecting the sector’s robust innovation momentum and the increasing interest in next-generation therapies. For instance, on May 19, 2025, Atsena Therapeutics announced encouraging results from Part A of its LIGHTHOUSE Phase I/II trial, evaluating ATSN-201 delivered subretinally as a treatment for X-linked retinoschisis (XLRS). Similarly, on April 30, 2025, Genprex, Inc. reported promising preclinical findings for its Reqorsa Gene Therapy (quaratusugene ozeplasmid), which targets the KRASG12C mutation in non-small cell lung cancer. These advancements indicate not only a growing list of viable therapeutic candidates but also increased confidence in the potential of cell and gene therapies to address complex and previously untreatable conditions, which in turn supports greater regulatory engagement and accelerates market approvals.

How will this Report Benefit you?

Visiongain’s 422-page report provides 176 tables, 204 charts/graphs. Our new study is suitable for anyone requiring commercial, in-depth analysis for the vaccine contract manufacturing market, along with detailed segment analysis in the market. Our new study will help you evaluate the overall global and regional market for cell and gene therapy cold chain logistics. Get financial analysis of the overall market and different segments including type, product and service, workflow, application, indication, end-user, and capture higher market share. We believe that there are strong opportunities in this fast-growing cell and gene therapy cold chain logistics market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report will help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company.

What are the Current Market Drivers?

Technological Innovations in Healthcare Cold Chain

Technological innovations are significantly reshaping the healthcare cold chain landscape, especially in the cell and gene therapy (CGT) sector, by boosting operational efficiency, enhancing real-time visibility, and introducing next-generation storage solutions. A major area of advancement is in cryogenic storage. For example, on April 16, 2024, CSafe unveiled a new line of cryogenic, multi-use dewars under its CGT Cryo Series. These containers are designed to sustain ultra-low temperatures below -150°C, making them ideal for the secure transport of sensitive and high-value biologics like CGT products. Such innovations are critical for maintaining product stability and ensuring safe global distribution, particularly over extended durations and across complex supply chains.

In parallel, digital transformation is playing an increasingly important role in cold chain logistics. On March 8, 2024, UPS launched UPS Supply Chain Symphony, a cloud-based digital platform aimed at healthcare clients. The system integrates data across multiple operational tools to provide a unified, real-time view of the entire logistics process. By offering detailed insights into shipment status, temperature compliance, and potential disruptions, platforms like Symphony empower companies to make faster, data-driven decisions. This combination of physical storage innovation and digital oversight is key to building a more resilient, responsive, and scalable cold chain ecosystem capable of supporting the growing global demand for advanced therapies.

Rising Adoption of Gene and Cell Therapies Propelling the Market Growth

Recent years have witnessed a noticeable surge in the adoption of cell and gene therapies, largely due to improvements in manufacturing technologies and more streamlined delivery mechanisms. Public awareness of these advanced therapies is also growing, supported by expanding patient access programs that make treatments more widely available. This has led to the approval of several novel therapies targeting complex conditions such as blood disorders and various cancers. As clinical evidence continues to build and more therapies reach the market, the momentum behind ATMP adoption is expected to accelerate, offering new hope for patients with previously untreatable or hard-to-treat diseases. 

Where are the Market Opportunities?

Lucrative Opportunities in Developing Countries 

The global expansion of the cell and gene therapy cold chain logistics market is creating substantial opportunities for logistics providers to enter emerging healthcare markets. Regions such as Asia Pacific, Latin America, and Africa are increasingly being recognized for their untapped potential, especially as demand for advanced biopharmaceutical treatments continues to grow. Companies like DHL, UPS, and FedEx are actively expanding their presence in these regions to bridge the gap in access to high-end therapies like cell and gene treatments. By establishing reliable and compliant cold chain logistics infrastructure, these providers are not only opening new revenue streams but also helping healthcare systems deliver life-saving therapies to previously underserved populations. Among these regions, Asia Pacific stands out as a particularly promising market due to its large and ageing population, rising healthcare investments, and growing prevalence of chronic and genetic diseases. Countries such as China, India, and Singapore are seeing increased demand for temperature-sensitive biologics, prompting logistics leaders to invest in specialized storage facilities, transportation capabilities, and local partnerships. 

Competitive Landscape

The major players operating in the cell and gene therapy cold chain logistics market are Cencora, Inc., Cardinal Health, Catalent Inc., Thermo Fisher Scientific Inc., Marken (a UPS Company), A.P. Møller – Maersk, CryoPort Inc., DHL, FedEx, Arvato SE, NMDP BioTherapies, BioLife Solutions Inc., BioStor Systems Inc., Yourway, Atelerix Ltd., Nordic Cold Chain Solutions, MasterControl Solutions, Inc., TrakCel, Modality Solutions, and sedApta s.r.l. These major players operating in the viral vectors and plasmid DNA market have adopted a range of strategies including mergers and acquisitions (M&A), strategic collaborations, increased investment in research and development (R&D), regional business expansions, partnerships, and the launch of new products to strengthen their market position and drive growth.

Recent Developments

• On 7 April 2025, BioLife Solutions, Inc. completed the acquisition of PanTHERA CryoSolutions, Inc., a private firm known for its proprietary IRI-based cryopreservation solutions. This move strengthens BioLife’s leadership in biopreservation and expands its consumable product offerings while adding scientific expertise to its management team.
• On 12 March 2025, Cryoport, Inc. launched the MVE Biological Solutions High-Efficiency 800 C, a compact cryogenic freezer designed for labs, fertility clinics, and biorepositories, combining user-friendly design and performance.
• On 25 February 2025, FedEx is strengthening its position in the UAE’s expanding healthcare sector by providing innovative logistics solutions specifically designed for pharmaceuticals, medical equipment, and medical research companies. At a recent Power Networking event, FedEx collaborated with key healthcare stakeholders to identify new strategies for enhancing supply chain efficiency and ensuring the prompt delivery of critical medical shipments.

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to contactus@visiongain.com or call +44 207 336 6100.

About Visiongain

Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.